Drug Trial Radar · NCT06297941
Study of REM-422 in Patients With AML or Higher Risk MDS
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Apr 26, 2024
Primary completion
Jul 31, 2027
Study completion Mar 30, 2028
Sponsor
- Lead sponsor
- Remix TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML
Conditions
- Myelodysplastic Syndromes
- Higher Risk Myelodysplastic Syndromes
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Refractory
Interventions
REM-422Drug
REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor REM-422 will be administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of Treatment Emergent Adverse Events (TEAEs)Time frame: 24 months
- Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)Time frame: Assessed at the end of Cycle 1 (each cycle is 28 days) for each participant for approximately 24 months
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Memorial Sloan Kettering
New York, New York · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Centre Hospitalier Universitaire (CHU) de Bordeaux
Bordeaux, France · Recruiting
AP-HP - Hôpital Saint-Louis
Paris, France · Recruiting
IUCT-Oncopole
Toulouse, France · Recruiting
Institut de Cancerologie Gustave-Roussy
Villejuif, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.